121 related articles for article (PubMed ID: 7996875)
1. Influence of idarubicinol on the antileukemic effect of idarubicin.
Fukushima T; Kawai Y; Urasaki Y; Yoshida A; Ueda T; Nakamura T
Leuk Res; 1994 Dec; 18(12):943-7. PubMed ID: 7996875
[TBL] [Abstract][Full Text] [Related]
2. Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin.
Fukushima T; Inoue H; Takemura H; Kishi S; Yamauchi T; Inai K; Nakayama T; Imamura S; Urasaki Y; Nakamura T; Ueda T
Leuk Res; 1998 Jul; 22(7):625-9. PubMed ID: 9680113
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
[TBL] [Abstract][Full Text] [Related]
4. Effect of PSC 833 on the cytotoxicity of idarubicin and idarubicinol in multidrug-resistant K562 cells.
Fukushima T; Yamashita T; Yoshio N; Misaki H; Yamauchi T; Imamura S; Urasaki Y; Ueda T
Leuk Res; 1999 Jan; 23(1):37-42. PubMed ID: 9933133
[TBL] [Abstract][Full Text] [Related]
5. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.
Kuffel MJ; Reid JM; Ames MM
Cancer Chemother Pharmacol; 1992; 30(1):51-7. PubMed ID: 1586980
[TBL] [Abstract][Full Text] [Related]
6. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
[TBL] [Abstract][Full Text] [Related]
7. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
Roovers DJ; van Vliet M; Bloem AC; Lokhorst HM
Leuk Res; 1999 Jun; 23(6):539-48. PubMed ID: 10374847
[TBL] [Abstract][Full Text] [Related]
8. A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia.
Fukushima T; Yamashita T; Goto N; Ueda T; Okabe KI; Kuraishi Y; Ohno R; Urabe A; Ogawa M
Int J Hematol; 2001 Oct; 74(3):297-302. PubMed ID: 11721966
[TBL] [Abstract][Full Text] [Related]
9. Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells.
Tidefelt U; Prenkert M; Paul C
Cancer Chemother Pharmacol; 1996; 38(5):476-80. PubMed ID: 8765443
[TBL] [Abstract][Full Text] [Related]
10. Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells.
Chiodini B; Bassan R; Barbui T
Leuk Lymphoma; 1999 May; 33(5-6):485-97. PubMed ID: 10342576
[TBL] [Abstract][Full Text] [Related]
11. Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study.
Camaggi CM; Strocchi E; Carisi P; Martoni A; Tononi A; Guaraldi M; Strolin-Benedetti M; Efthymiopoulos C; Pannuti F
Cancer Chemother Pharmacol; 1992; 30(4):307-16. PubMed ID: 1643700
[TBL] [Abstract][Full Text] [Related]
12. Comparative activity of idarubicin and idarubicinol in combination with cyclosporin A in multidrug-resistant leukemia cells.
Tolomeo M; Gancitano RA; Musso M; Porretto F; Perricone R; Abbadessa V; Cajozzo A
Cancer Chemother Pharmacol; 1996; 39(1-2):157-61. PubMed ID: 8995514
[TBL] [Abstract][Full Text] [Related]
13. Low-dose long-term oral idarubicin in maintenance treatment of elderly acute myeloid leukemia.
Musso M; Porretto F; Crescimanno A; Bondì F; Polizzi V; Scalone R; Tolomeo M; Mariani G
Haematologica; 1997; 82(5 Suppl):4-8. PubMed ID: 9402746
[TBL] [Abstract][Full Text] [Related]
14. High-performance liquid chromatographic analysis of idarubicin and fluorescent metabolites in biological fluids.
Camaggi CM; Carisi P; Strocchi E; Pannuti F
Cancer Chemother Pharmacol; 1992; 30(4):303-6. PubMed ID: 1643699
[TBL] [Abstract][Full Text] [Related]
15. Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia.
Pea F; Damiani D; Michieli M; Ermacora A; Baraldo M; Russo D; Fanin R; Baccarani M; Furlanut M
Eur J Clin Pharmacol; 1999 Jul; 55(5):361-8. PubMed ID: 10456485
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells.
Limonta M; Biondi A; Giudici G; Specchia G; Catapano C; Masera G; Barbui T; D'Incalci M
Cancer Chemother Pharmacol; 1990; 26(5):340-2. PubMed ID: 2208574
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance.
Smeets M; Raymakers R; Muus P; Vierwinden G; Linssen P; Masereeuw R; de Witte T
Leukemia; 2001 Jan; 15(1):80-8. PubMed ID: 11243404
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic self-potentiation of idarubicin by induction of anthracycline carbonyl reducing enzymes.
Yamashita T; Fukushima T; Ueda T
Leuk Lymphoma; 2008 Apr; 49(4):809-14. PubMed ID: 18398750
[TBL] [Abstract][Full Text] [Related]
19. Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite--a comparison of bolus versus 2 h infusion during a 3 day course.
Eksborg S; Björkholm M; Hast R; Fagerlund E
Anticancer Drugs; 1997 Jan; 8(1):42-7. PubMed ID: 9147610
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
Tsuruo T; Oh-Hara T; Sudo Y; Naito M
Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]